A BrightFocus-funded team has identified a potential way to diagnose a rare but devastating form of early Alzheimer’s disease by examining cells of the inner eye.
The U.S. Food and Drug Administration today granted full approved of Leqembi (lecanemab-irmb) for the treatment of Alzheimer’s disease based on its ability to clear toxic amyloid from the brain.
In a finding that raises new questions about the connection between amyloid plaques and Alzheimer’s disease, a Dutch study showed people over age 100 maintained sharp minds despite having brain changes associated with dementia.
The FDA has approved the use of atypical antipsychotic drug Rexulti (brexpiprazole) for treating agitation associated with Alzheimer’s dementia, making it the first FDA-approved treatment for Alzheimer’s agitation in the U.S.
A BrightFocus-funded research team has some eye-opening news: They’ve used artificial intelligence to develop a model that could one day detect Alzheimer’s disease through photographs of the eye, which could lead to earlier diagnosis and treatment.
Researchers have identified a new gene region in people of African descent that reduces Alzheimer's disease risk—highlighting the importance of diversity and inclusion of all populations in research.
A BrightFocus Foundation-funded study found that even moderate alcohol use can cause changes in the brain that may accelerate Alzheimer’s disease, shedding new light on a possible modifiable risk factor for dementia.
BrightFocus-funded research offers new evidence of the importance of tau in the prediction of Alzheimer’s disease which could lead to ways to delay—or even stop—the disease from progressing.